KALV EBITDA Growth
Kalvista Pharmaceuticals Inc · EBITDA Growth
KALV EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported32.33%period ending
KALV TTM EBITDA YoY % (-111.61% → 32.33%)
Year-over-year change
High-resolution chart · PNG
KALV ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 32.3326% | |
| 2.3552% | |
| -20.6165% | |
| -32.891% | |
| -37.7499% | |
| -56.1466% | |
| -55.8258% | |
| -49.237% | |
| -36.4892% | |
| -19.4226% | |
| -9.3761% | |
| -6.4805% | |
| -12.7349% | |
| -18.8973% | |
| -38.4084% | |
| -50.1863% | |
| -42.4999% | |
| -56.7345% | |
| -36.6705% | |
| -32.3531% | |
| -44.8995% | |
| -15.2595% | |
| -33.8857% | |
| -40.3397% | |
| -34.5062% | |
| -97.4887% | |
| -89.9858% | |
| -58.4509% | |
| -58.942% | |
| -2.6206% | |
| 22.5779% | |
| -7.8483% | |
| -40.618% | |
| -41.3962% | |
| -103.1604% | |
| -9.9337% | |
| 41.6098% | |
| 30.1314% | |
| 38.282% | |
| 7.4744% | |
| -48.444% | |
| -71.2755% | |
| -111.613% |